Teva’s new plant no longer idle
Executive Summary
Teva's new Jerusalem plant passed FDA inspection last month and is now operating, the generic firm announces during an analyst call Feb. 13. The plant was scheduled to be fully operational in early 2006 (1"The Pink Sheet" Aug. 14, 2006, p. 6). CEO Israel Makov says the plant started with a capacity of four billion tablets a year, with a goal to double that by year end...
You may also be interested in...
Teva’s Generic Zoloft Launch, And New Jerusalem Plant, Remain Idle
Teva's supply chain challenges appear to have caught up with the company in the form of further delays of its launch of Zoloft generics
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.